Table 3.

Summary of steady-state pharmacokinetics of mericitabine and ribavirin

	Treatment
Pharmacokinetic parameter	Mericitabine 500 mg (n = 14)	Mericitabine 1000 mg (n = 59)	Mericitabine placebo (n = 35)
Mericitabine
Mean Cmax ± SD (μg ml−1)	5.70 ± 1.36	9.26 ± 1.85	NA
Mean AUCτ ± SD (μg h ml−1)	37.0 ± 8.51a	60.3 ± 10.5b	NA
Median Tmax [h (range)]	2.0 (1.0–4.0)	2.0 (0.5–6.5)	NA
Mean Cmin ± SD (μg ml−1)	1.24 ± 0.496a	2.01 ± 0.79b	NA
Ribavirin
Mean Cmax ± SD (μg ml−1)	3.53 ± 1.33	2.96 ± 0.79	3.27 ± 0.98
Mean AUCτ ± SD (μg h ml−1)	32.60 ± 11.70c	28.50 ± 6.99d	30.00 ± 7.39f
Median Tmax [h (range)]	2.0 (0.5–4.0)	2.2 (0.5–6.0)	2.0 (0.5–6.2)
Mean Cmin ± SD (μg ml−1)	2.35 ± 0.80c	2.05 ± 0.53e	2.20 ± 0.56g

Abbreviations are as follows: AUC_τ, area under the plasma concentration–time curve from 0 to the end of the dosing interval; C_max, maximum observed plasma concentration; C_min, minimum observed plasma concentration (measured 12 h postdose); NA, not applicable; T_max, time to reach C_max.

^an = 13;

^bn = 57;

^cn = 13;

^dn = 53;

^en = 56;

^fn = 29;

^gn = 30.